Format

Send to

Choose Destination
Curr Opin Investig Drugs. 2002 Jul;3(7):1089-91.

Immunotoxins in cancer therapy.

Author information

1
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA. pasta@helix.nih.gov

Abstract

Several antibodies have now been approved for the therapy of cancer. Two of these, rituximab (Rituxan) and alemtuzumab (CAMPATH; ILEX Oncology Inc), are capable of inducing cell death and tumor regressions when given alone. The third, trastuzumab (Herceptin), is not very effective by itself, but does potentiate the activity of paclitaxel (Taxol) and other chemotherapeutic agents. Unfortunately, most antibodies do not kill cancer cells unless they are armed with a cytotoxic agent, such as a radioisotope, a cytotoxic drug, or a protein toxin. Each of these have advantages and disadvantages.

PMID:
12186272
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center